推荐产品
等級
pharmaceutical primary standard
API 家族
citalopram
製造商／商標名
USP
應用
pharmaceutical (small molecule)
格式
neat
SMILES 字串
Br[H].CN(C)CCCC1(OCc2cc(ccc12)C#N)c3ccc(F)cc3
InChI
1S/C20H21FN2O.BrH/c1-23(2)11-3-10-20(17-5-7-18(21)8-6-17)19-9-4-15(13-22)12-16(19)14-24-20;/h4-9,12H,3,10-11,14H2,1-2H3;1H
InChI 密鑰
WIHMBLDNRMIGDW-UHFFFAOYSA-N
基因資訊
human ... SLC6A4(6532)
正在寻找类似产品? 访问 产品对比指南
一般說明
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
應用
Citalopram hydrobromide USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
- Citalopram Oral Solution
- Citalopram Tablets
- Escitalopram Tablets
生化／生理作用
有效的选择性 5-羟色胺摄取抑制剂 (Ki = 5.4 nM)；抗抑郁药
分析報告
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
其他說明
Sales restrictions may apply.
相關產品
产品编号
说明
价格
訊號詞
Warning
危險分類
Acute Tox. 4 Oral - Aquatic Chronic 3 - Repr. 2 - STOT SE 3
標靶器官
Central nervous system
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 2
閃點（°F）
Not applicable
閃點（°C）
Not applicable
其他客户在看
Yevheniia Mikheenko et al.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 40(6), 1395-1404 (2015-01-15)
Trait anxiety is a risk factor for the development and maintenance of affective disorders, and insights into the underlying brain mechanisms are vital for improving treatment and prevention strategies. Translational studies in non-human primates, where targeted neurochemical and genetic manipulations
Gordon F Buchanan et al.
The Journal of physiology, 592(19), 4395-4410 (2014-08-12)
Sudden unexpected death in epilepsy (SUDEP) is the leading cause of death in patients with refractory epilepsy. Defects in central control of breathing are important contributors to the pathophysiology of SUDEP, and serotonin (5-HT) system dysfunction may be involved. Here
M D Opal et al.
Molecular psychiatry, 19(10), 1106-1114 (2013-10-30)
Current antidepressants must be administered for several weeks to produce therapeutic effects. We show that selective serotonin 2C (5-HT2C) antagonists exert antidepressant actions with a faster-onset (5 days) than that of current antidepressants (14 days) in mice. Subchronic (5 days)
Mark R Davies et al.
Cell reports. Medicine, 1(5), 100076-100076 (2020-11-19)
There is an increasing expectation that computational approaches may supplement existing human decision-making. Frontloading of models for cardiac safety prediction is no exception to this trend, and ongoing regulatory initiatives propose use of high-throughput in vitro data combined with computational models
Laura Jiménez-Sánchez et al.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 39(11), 2673-2680 (2014-05-30)
Paradoxically, N-methyl-D-aspartate (NMDA) receptor antagonists are used to model certain aspects of schizophrenia as well as to treat refractory depression. However, the role of different subunits of the NMDA receptor in both conditions is poorly understood. Here we used biochemical
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门